GRNOPC1
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Cord Injury
Conditions
Spinal Cord Injury
Trial Timeline
Oct 1, 2010 → Jul 1, 2013
NCT ID
NCT01217008About GRNOPC1
GRNOPC1 is a phase 1 stage product being developed by Lineage Cell Therapeutics for Spinal Cord Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT01217008. Target conditions include Spinal Cord Injury.
What happened to similar drugs?
7 of 20 similar drugs in Spinal Cord Injury were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01217008 | Phase 1 | Completed |
Competing Products
20 competing products in Spinal Cord Injury